Impact of low-dose calcipotriol ointment on wound healing, pruritus and pain in patients with dystrophic epidermolysis bullosa: A randomized, double-blind, placebo-controlled trial.
Christina Guttmann-GruberJosefina Piñón HofbauerBirgit TocknerVictoria ReichlAlfred KlauseggerPeter HofbauerMartin WolkersdorferKhek-Chian ThamSeong Soo LimJohn E CommonAnja DiemKatharina Ude-SchoderWolfgang HitzlFlorian LaglerJulia ReicheltJohann W BauerRoland LangMartin LaimerPublished in: Orphanet journal of rare diseases (2021)
Our results show that topical treatment with low-dose calcipotriol can accelerate wound closure and significantly reduces itch, and can be considered a safe and readily-available option to improve local wound care in DEB patients. Trial Registration EudraCT: 2016-001,967-35. Registered 28 June 2016, https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001967-35/AT.
Keyphrases
- low dose
- wound healing
- study protocol
- double blind
- phase iii
- clinical trial
- phase ii
- end stage renal disease
- high dose
- newly diagnosed
- healthcare
- chronic pain
- pain management
- ejection fraction
- chronic kidney disease
- placebo controlled
- randomized controlled trial
- palliative care
- neuropathic pain
- open label
- health insurance
- postoperative pain